期刊文献+

普拉格雷类似物的合成及抗血小板聚集活性 被引量:2

Synthesis and antiplatelet aggregation activities of prasugrel derivatives
下载PDF
导出
摘要 采用前药设计原理,以普拉格雷代谢物为先导化合物,设计并合成了一系列2-羟基四氢噻吩并吡啶烷氧羰基酯类衍生物(1~8),结构均经IR、1H NMR、13C NMR、MS和HRMS确证。对目标化合物进行了抗血小板聚集的药理活性评价,活性测试结果显示除化合物5外,其余大部分化合物都显示出较好的抗血小板聚集活性,部分化合物显示了与普拉格雷相当的抗血小板聚集活性。 With the metabolite of prasugrel as a lead compound,a series of 2-hydroxytetrahydrothienopyridine derivatives were designed and synthesized based on prodrug theory.Their structures were confirmed by IR,1 H NMR,13 C NMR,MS,and HRMS.The target compounds 1-8 were biologically evaluated for their antiplatelet aggregation activity.Except for compound 5,most of the test compounds exhibited potent antiplatelet aggregation activity,some exhibiting similar potent activity to prasugrel.The compounds are worthy of further study to search for novel antithrombotic agents with improved potency,safety profile and chemical stability.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2011年第4期305-309,共5页 Journal of China Pharmaceutical University
关键词 普拉格雷 结构修饰 2-羟基四氢噻吩并吡啶衍生物 合成 抗血小板聚集 prasugrel structural modification 2-hydroxytetrahydrothienopyridine derivatives synthesis anti-platelet aggregation
  • 相关文献

参考文献10

  • 1Michelson AD. Antiplatelet therapies for the treatment of cardio- vasculadisease [ J ]. Nat Rev Drug Discov, 2010, 9 ( 2 ) : 154 - 169.
  • 2Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combina- tion with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study ( CLASSICS ) [ J ]. Circula- tion,2000,102 ( 6 ) :624 - 629.
  • 3Michos ED, Ardehali R, Blumenthal RS ,et al. Aspirin and clopi- dogrel resistance [ J ]. Mayo Clin Proc, 2006,81 ( 4 ) : 518 - 526.
  • 4Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance [ J ]. Circulation, 2004, 109 ( 2 ) : 166 - 171.
  • 5Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo anti- platelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar anti- platelet activity to that of clopidogrel's active metabolite [ J ]. J Thromb Haemost,2007,5 (7) : 1 545 - 1 551.
  • 6Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes [ J ]. N En- gl J Med,2007,357(20) :2 001 -2 015.
  • 7Dziennik DB,Edelman TB, Oren PL,et al. Formulation of a thienopyridine platelet aggregation inhibitor: WO, 2006135605 A2 [ P]. 2006-12-21 [2011-03-21 ].
  • 8Badorc A, Frehel D, Maffrand JP, et al. Derivatives of alpha-( 2- oxo 2,4,5,6,7,7a-hexahydro thieno[3,2-c]5-pyridyl) phenyl acetic acid, and their use as platelet and thrombotic aggregation inhibitors : US,4740510 [ P]. 1988-04-26[2011-03-21 ].
  • 9Hiroyuki K, Fumitoshi A, Atsuhiro S, et al. Tetrahydrothienopyri- dine derivatives, Furo and Pyrrolo analogs thereof and their prep- aration and uses for inhibiting blood platelet aggregation: EP, 0542411 [ P]. 1993-05-19[2011-03-21 ].
  • 10Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal[J]. Nature,1962,194(4 832) :927 -929.

同被引文献17

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部